BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 27286362)

  • 1. Investigational targeted therapies for the treatment of testicular germ cell tumors.
    Oing C; Kollmannsberger C; Oechsle K; Bokemeyer C
    Expert Opin Investig Drugs; 2016 Sep; 25(9):1033-43. PubMed ID: 27286362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promising novel therapies for relapsed and refractory testicular germ cell tumors.
    Kozakova K; Mego M; Cheng L; Chovanec M
    Expert Rev Anticancer Ther; 2021 Jan; 21(1):53-69. PubMed ID: 33138660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platinum-refractory germ cell tumors: an update on current treatment options and developments.
    Oing C; Alsdorf WH; von Amsberg G; Oechsle K; Bokemeyer C
    World J Urol; 2017 Aug; 35(8):1167-1175. PubMed ID: 27449639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of refractory germ-cell tumours with single-agent cabazitaxel: a German Testicular Cancer Study Group case series.
    Oing C; Hentrich M; Lorch A; Gläser D; Rumpold H; Ochsenreither S; Richter S; Dieing A; Zschäbitz S; Pereira RR; Bokemeyer C; Seidel C
    J Cancer Res Clin Oncol; 2020 Feb; 146(2):449-455. PubMed ID: 31838576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to anti-programmed cell death protein-1 antibodies in men treated for platinum refractory germ cell cancer relapsed after high-dose chemotherapy and stem cell transplantation.
    Zschäbitz S; Lasitschka F; Hadaschik B; Hofheinz RD; Jentsch-Ullrich K; Grüner M; Jäger D; Grüllich C
    Eur J Cancer; 2017 May; 76():1-7. PubMed ID: 28262583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFRβ/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial.
    Subbiah V; Meric-Bernstam F; Mills GB; Shaw KR; Bailey AM; Rao P; Ward JF; Pagliaro LC
    J Hematol Oncol; 2014 Aug; 7():52. PubMed ID: 25085632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Third-line chemotherapy and novel agents for metastatic germ cell tumors.
    Veenstra CM; Vaughn DJ
    Hematol Oncol Clin North Am; 2011 Jun; 25(3):577-91, ix. PubMed ID: 21570610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging Therapeutic Targets for Male Germ Cell Tumors.
    Fankhauser CD; Honecker F; Beyer J; Bode PK
    Curr Oncol Rep; 2015 Dec; 17(12):54. PubMed ID: 26449842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacotherapeutic treatment of germ cell tumors: standard of care and recent developments.
    Oing C; Seidel C; von Amsberg G; Oechsle K; Bokemeyer C
    Expert Opin Pharmacother; 2016; 17(4):545-60. PubMed ID: 26630452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of everolimus in refractory testicular germ cell tumors.
    Mego M; Svetlovska D; Miskovska V; Obertova J; Palacka P; Rajec J; Sycova-Mila Z; Chovanec M; Rejlekova K; Zuzák P; Ondrus D; Spanik S; Reckova M; Mardiak J
    Urol Oncol; 2016 Mar; 34(3):122.e17-22. PubMed ID: 26612480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apoptosis regulation and spontaneous apoptosis index of testicular germ cell tumors are associated with differentiation and resistance to systemic treatment.
    Mandoky L; Szende B; Géczi L; Bodrogi I; Kásler M; Bak M
    Anticancer Res; 2008; 28(3A):1641-9. PubMed ID: 18630521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic approaches for refractory germ cell cancer.
    Oing C; Seidel C; Bokemeyer C
    Expert Rev Anticancer Ther; 2018 Apr; 18(4):389-397. PubMed ID: 29516750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted treatment approaches in refractory germ cell tumors.
    Galvez-Carvajal L; Sanchez-Muñoz A; Ribelles N; Saez M; Baena J; Ruiz S; Ithurbisquy C; Alba E
    Crit Rev Oncol Hematol; 2019 Nov; 143():130-138. PubMed ID: 31634730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic treatment combinations to effectively target cisplatin-resistant germ cell tumors: past, present, and future considerations.
    Oing C; Skowron MA; Bokemeyer C; Nettersheim D
    Andrology; 2019 Jul; 7(4):487-497. PubMed ID: 30924611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting of Deregulated Wnt/β-Catenin Signaling by PRI-724 and LGK974 Inhibitors in Germ Cell Tumor Cell Lines.
    Schmidtova S; Kalavska K; Liskova V; Plava J; Miklikova S; Kucerova L; Matuskova M; Rojikova L; Cierna Z; Rogozea A; Konig H; Albany C; Mego M; Chovanec M
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33923996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of
    Timmerman DM; Eleveld TF; Gillis AJM; Friedrichs CC; Hillenius S; Remmers TL; Sriram S; Looijenga LHJ
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of N-cadherin in proliferation, migration, and invasion of germ cell tumours.
    Bremmer F; Schallenberg S; Jarry H; Küffer S; Kaulfuss S; Burfeind P; Strauß A; Thelen P; Radzun HJ; Ströbel P; Honecker F; Behnes CL
    Oncotarget; 2015 Oct; 6(32):33426-37. PubMed ID: 26451610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Further insights into testicular germ cell tumor oncogenesis: potential therapeutic targets.
    Chieffi P; De Martino M; Esposito F
    Expert Rev Anticancer Ther; 2020 Mar; 20(3):189-195. PubMed ID: 32164473
    [No Abstract]   [Full Text] [Related]  

  • 19. Targeted therapies in the treatment of germ cell tumors: the need for new approaches against "orphan" tumors.
    Sánchez-Muñoz A; Jiménez-Rodríguez B; Navarro-Pérez V; Medina-Rodríguez L; Llácer C; Vicioso L; Machuca J; Alba E
    Crit Rev Oncol Hematol; 2012 Sep; 83(3):444-51. PubMed ID: 22230258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current Management of Refractory Germ Cell Tumors and Future Directions.
    Allen JC; Kirschner A; Scarpato KR; Morgans AK
    Curr Oncol Rep; 2017 Feb; 19(2):8. PubMed ID: 28220447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.